Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
RMC5127 | 选择性RAS G12V抑制剂 | CNS&脑渗透性 | 抗肿瘤 | TargetMol
RMC5127 | Ras inhibitor | Selleck
RMC5127 | Ras inhibitor | CAS 3056146-38-1 | Selleck
RMC5127 | 突变选择性RAS G12V抑制剂 | 抗肿瘤 | TargetMol
RMC5127 | Ras inhibitor | ≥99%(HPLC) | In Stock
RMC5127 | Selective RAS G12V inhibitor | Brain-penetrant | TargetMol
RMC5127 | Mutant-selective RAS G12V inhibitor | Antitumor | TargetMol
RMC-5127
2025 AACR 大会：星光闪耀下的明星分子与关键分子砌块揭秘 | 乐研试剂
RMC-5127 and the Future of Targeting KRAS Mutations in Cancer Therapy
RMC-5127 - ChemicalBook
RMC-5127 CAS#: 3082166-76-2
RMC-5127 - Chemietek
RMC-5127 上海 - ChemicalBook
RMC-5127｜ KRAS G12V 抑制剂的合成与供应信息 - Book学术
AACR24|RMC-6236结构正式公开，那些年它的follower们_财富号_东方财富网
Revolution Medicines doses first RMC-5127 patient | RVMD Stock News
RMC-5127 品牌:魏氏试剂 湖北 - ChemicalBook
RMC-5127 品牌:杰瑞兴 上海 - ChemicalBook
晚期实体瘤患者新希望：新药RMC-5127正式开启人体临床试验，面向RAS G12V突变型胰腺癌、肠癌、肺癌等患者-出国看病-盛诺一家
Abstract 3340: RMC-5127, a first-in-class, orally bioavailable mutant ...
RMC-5127 | GTP-bound KRAS^{G12V} Inhibitor | MedChemExpress
pan-RAS inhibitor RMC-5127 intermediate - ChemicalBook
RMC-5127, a novel tri-complex inhibitor with efficacy in KRAS G12V ...
TiPLab - 2025AACR年会揭晓的12种新型抗癌药物之：下一代精准KRAS小分子抑制剂
RMC-5127 | RASG12V(ON)抑制剂 | MCE
RMC-5127 - Drug Targets, Indications, Patents - Synapse
RMC-5127 突变选择性三重复合物 RASG12V 的抑制剂 | MedChemExpress (MCE 中国)_癌细胞_产品_rmmc
RMC-5127(RMC-5127) - 药物靶点：KRAS G12V_在研适应症：晚期恶性实体瘤，结直肠癌，非小细胞肺癌_专利_临床_研发
AZD3514 | Androgen Receptor | TargetMol
Revolution：RAS(ON) 12V抑制剂启动一期临床 Armstrong 2026年1月16日， Revolution ...
RAS抑制剂研发热潮！RMC-7977和RMC-6236抑制剂有望为RAS突变型肿瘤的治疗带来新希望
Revolution Medicines Doses First Patient in Clinical Trial Evaluating ...
First Patient Dosed in Ph 1 Trial of RMC-5127 in patients with RAS G12V ...
RMC系列小分子化合物概览：RMC-9805、RMC-5127、RMC-5552、RMC-6291、RMC-7977、RMC-0708、RMC ...
RMC-5127 突变选择性三重复合物 RASG12V 的抑制剂
RMC-5127 KRAS G12V 抑制剂 | DKM活性分子
RMC-5127 品牌:Afflon 四川成都 - ChemicalBook
RMC-5127(RMC-5127) - 药物靶点：KRAS G12V_在研适应症：非小细胞肺癌，胰腺导管腺癌_专利_临床_研发
科学网—2025 AACR 大会：星光闪耀下的明星分子与关键分子砌块揭秘 | 乐研试剂 - 陈谦的博文
A Look At Revolution Medicines (RVMD) Valuation After First Patient ...
价格：降，再降，一路下降 | RMC-5127的重要中间体的需求与供应 - Book学术
RMC 5127 - AdisInsight
挑战“癌王”_财富号_东方财富网
KRASG12D（ON）抑制剂RMC-9805结构与临床前数据公开_财富号_东方财富网
